Analysis and significance of hematopoietic progenitor B cells in patients with acute leukemia.
10.7534/j.issn.1009-2137.2014.06.005
- Author:
Yan-Li XU
1
;
Shun-Qing WANG
2
;
Ping MAO
2
;
Qing-Hua DU
2
Author Information
1. Department of Hematology, Guangzhou First Municipal Peoples' Hospital, Guangzhou 510180, Guangdong Province, China. E-mail: chenxuyanli@163.com.
2. Department of Hematology, Guangzhou First Municipal Peoples' Hospital, Guangzhou 510180, Guangdong Province, China.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Cell Differentiation;
Flow Cytometry;
Hematopoietic System;
Humans;
Immunophenotyping;
Leukemia;
pathology;
Neoplasm Recurrence, Local;
Neoplasm, Residual;
Precursor Cells, B-Lymphoid;
pathology
- From:
Journal of Experimental Hematology
2014;22(6):1525-1530
- CountryChina
- Language:Chinese
-
Abstract:
Normal hematopoietic B progenitor cells are similar with acute B lymphoblastic leukemia (ALL) cells in terms of morphology and immunophenotypes which easily result in misdiagnosis of diseases. This study was purposed to explore the importance of B progenitor cell (BPC) level in differential diagnosis of hematologic diseases. A total of 664 specimens including 87 specimens from patients with non-malignant hematologic diseases as control and 577 specimens from AL patients in different progressive stage were analyzed. Out of 577 specimens 26 were collected from ALL patients, 261 were collected from B-ALL, 290 were collected from AML. The relation of different clinical status (new diagnosis, remission, relapse), age and degree of leukemia cell involvement with hematopoietic BPC level were analyzed through identification of CD34/CD10/CD19/CD45 antibody combination and quantification of hematopoietic BPC. The results indicated that (1) CD45 distributed from positive to weak positive, and with very low side scatter. The early hematopoietic BPC expressed CD34⁺, along with increasing of cell maturation, the CD34 expression gradually disappeared, while CD19 and CD10 showed positive in whole stage of hemaropoietic BPC, and early CD10 highly was expressed. (2) the mean percentage of hematopoietic BPC was 1.36% in control group, 0.60% in T-ALL, 1.39% in B-ALL and 0.80% in AML; the detected rate of hematopoietic BPC in control, T-ALL, B-ALL and AML were 87.4%, 61.5%, 83.5%, 75.9%, respectively; the mean percentage of hematopoietic BPC was 0.37% at new diagnosis, 1.66% in remission and 0.55% in relapse. (3) along with increase of age, the hematopoietic BPC level generally disclined. (4) specimens >5% hematopoietic BPC were mainly found in remission stage of leukemia patients. It is concluded that the hematopoietic BPC are present in malignant and non-malignant hematologic diseases. The changes of hematopoietic BPC level correlate with disease state, age and leukemia cell involvement. The increased hematopoietic BPC level are observed most often in the patients with remission after themotherapy. It should be carefully to diagnose and discriminate between malignant and benign cells with double positive CD19 and CD10. Use of multiparametric flow cytometry and optimal antibody combination are important for discriminating hematopoietic BPC from minor residual disease and accuratly diagnosing diseases and evaluating curative effectiveness.
